---
title: "Halozyme director Matthew L. Posard disposes of common shares worth USD 2.02 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299366850.md"
description: "Halozyme Therapeutics director Matthew L. Posard sold 18,996 common shares on September 16, 2026, at an average price between $106.13 and $108.99, totaling approximately USD 2.02 million. Following this transaction, his direct shareholding decreased to 58,839 shares."
datetime: "2026-09-17T21:20:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299366850.md)
  - [en](https://longbridge.com/en/news/299366850.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299366850.md)
generator: "portal-rs"
---

# Halozyme director Matthew L. Posard disposes of common shares worth USD 2.02 million

-   Halozyme director Matthew L. Posard sold 18,996 common shares on Sept. 16, 2026 at prices averaging about $106.13 to $108.99. \* Posard’s direct holding fell to 58,839 shares following the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001159036-26-000123), on September 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [HALO.US](https://longbridge.com/en/quote/HALO.US.md)

## Related News & Research

- [Halozyme director Matthew L. Posard sells USD 569,752 common shares](https://longbridge.com/en/news/300826266.md)
- [Halozyme Therapeutics (HALO) Adds Jim Daly As Valuation Questions Follow](https://longbridge.com/en/news/300881155.md)
- [Halozyme wins Dutch court injunction blocking Merck Keytruda SC in eight European markets over EP622 patent](https://longbridge.com/en/news/301144513.md)
- [Nebius COO Nave Ophir disposes of USD 113.38 million in Class A shares](https://longbridge.com/en/news/301073075.md)
- [Personalis-Tempus AI deal clears US antitrust waiting period under HSR Act](https://longbridge.com/en/news/301072040.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**